Key Players

founder

Vijendra Nalamothu, Ph.D.

Dr. Nalamothu has been a leader in topical pharmaceutical development for more than two decades. He holds several patents and his efforts have led to a number of successful commercial products. His passion is to develop products that speak for themselves, leading him to be a co-founder of Tergus, shepherding the company to its industry leading position in the marketplace.

After earning his PhD in Pharmaceutics from the University of the Science’s Philadelphia College of Pharmacy, he worked at Sanofi-aventis Worldwide Dermatology (Dermik) as the Head of the Early Compound Assessment and Preclinical Group. He has also served as Global Head of Dermatology R&D at Promius Pharma, a wholly-owned subsidiary of Dr. Reddy’s Laboratories, where he spearheaded the development of specialty branded dermatological products from concept to commercialization.

Dr. Nalamothu’s interests include novel dosage form design and development of topical drug products. His commitment to quality and excellence led him to create the first Quality by Design (QbD) program for topicals, numerous articles and accolades. He is a sought-after speaker at conferences worldwide.

CEO and Co-founder

male

Kailas Thakker, Ph.D.

Dr. Thakker is a pioneer in functional testing for semi-solids, which led her to co-founding Tergus. Under her leadership, Tergus has emerged as the recognized global leader in developing release rate methods for semi-solid dosage forms.

She was involved in the development of in Vitro Release Testing (IVRT), recognized as an essential testing protocol for Semi-solid dosage forms. Her work led to the development of the SUPAC-SS guidance document that the pharmaceutical industry follows. She is a member of the USP’s Advisory Panel and helped draft chapters 3 and 1724. She is a member of USP’s Expert Committee on Dosage forms for the current revision cycle.

Dr. Thakker earned her PhD in Pharmaceutical Chemistry at the University of Kansas. She worked at US Pharmacopeia for 12 years, where she specialized in the development and validation of dissolution methods in the Drug Research and Testing Laboratory. Dr. Thakker has also held leadership positions at Sphinx Pharmaceuticals and BioAnalytika Laboratories.

With the emergence of newer, alternative dosage forms over the past 10 years, she has surfaced as a well-recognized global leader in the development of topical drug products, providing expertise in the development and validation of performance tests used to evaluate the transport of drugs across skin and other membranes (e.g., buccal, sublingual, vaginal, rectal). Working with compendial and regulatory organizations, Dr. Thakker continues to strive toward improving public standards for topical and other dosage forms.

COO and Co-Founder

male

Ryan Klein, Ph.D.

Dr. Klein earned his bachelor’s degree in Chemistry from Wake Forest University and his doctoral degree in Pharmaceutical Sciences from the School of Pharmacy at the University of North Carolina at Chapel Hill. He has over seventeen years of experience in the pharmaceutical industry in drug metabolism and pharmacokinetics. Ryan has a strong analytical background with extensive experience developing and validating in vitro release testing methods, as well as HPLC assay and impurities methods for drug substance and drug products for various dosage forms.

Before joining Tergus, Dr. Klein was at GlaxoSmithKline, where he was an integral component of their drug discovery organization designing and interpreting pre-clinical in vivo pharmacokinetic and in vitro ADME studies. He was instrumental in the development and implementation of a number of in vitro and in situ models to assess drug absorption, metabolism, and disposition. His areas of expertise include drug permeability, absorption and metabolism in the skin and gastrointestinal tract, intestinal drug transporters, and the anatomy, physiology, and pharmacology of the skin and gastrointestinal tract.

Ryan has authored/co-authored numerous scientific publications and patents, serves as a member of several pharmaceutical research focus and discussion groups.

Director of In Vitro Sciences

male

Jeff Reynolds

Jeffrey Reynolds heads the product development and clinical supplies manufacturing groups at Tergus. Jeff has supported many phases of drug product development including early phase pre-IND to phase I/II/II clinicals, and life cycle management and post approval support. He has worked with small, medium, and large companies, including GlaxoSmithKline, Church & Dwight, and KIK Custom Products. He is co-inventor on two patents, a number of patents-pending and has co-authored one article. His professional experience includes research and development of many types of pharmaceutical dosage forms including, solid and semi-solid across a broad spectrum of therapeutic areas (dermatology, GI, CNS, URT). Jeff brings a broad base of practical knowledge and experience with close to 30 years of professional experience combined with a strong academic background, which enables him to drive for solutions in both the scientific and management arenas. Jeff is a member of the AAPS, the SCC, and Delta Mu Delta as well as having served as an executive board member for the aerosol products division of the CSPA.

Associate Director of Pharmaceutical Sciences

male

Katrina Travis

Katrina Travis brings more than 20 years of experience to Tergus, helping to drive a quality culture by managing and implementing solid GxP Quality Systems. Her expertise includes quality systems, for example, CAPA, SOP, Change Control, Validation and Approved Suppliers, as well as optimal business, manufacturing and laboratory operations. Katrina contributes materially to the company-wide commitment to quality that Tergus is known for.

Katrina graduated from Barton College, with a BS in Chemistry and Math. Prior experience includes manager to director-level work in quality, training, internal audits, cGMP inspections and audits, regulatory compliance and/or laboratory testing for companies like Catalent Pharma Solutions, Envisia Therapeutics/Liquidia Technologies, Impact Fulfillment Services and Compuchem Labs. She is known in the industry for her expertise in GMP, Quality Assurance, Change Control, Six-Sigma, HPLC, Manufacturing and Continuous Improvement.

Director of Quality Assurance and Compliance